The specter of generic challenges has repeatedly loomed above copyright’s famous drug, Sildenafil, raising questions about the future of connected pharmaceutical investments. While early periods saw impressive gains, the exclusivity end has opened the way for cheaper alternatives, possibly lowering earnings and creating a real hazard for investor